Krishna Institute of Medical Sciences Limited has officially submitted its audited Standalone and Consolidated Financial Statements for the fiscal year ending March 31, 2026. These results, previously approved by the Board of Directors, are now available for shareholders’ adoption. The company also confirmed that these statements, along with audit reports, are accessible on their investor relations website.
Financial Statement Submission
Krishna Institute of Medical Sciences Limited has formally announced the submission of its audited Standalone and Consolidated Financial Statements. These statements cover the financial year that concluded on March 31, 2026. This filing follows the Board of Directors’ approval during their meeting on May 15, 2026, where the financial results were considered and sanctioned.
Key Details of the Filing
The submitted documents include the comprehensive audited Standalone and Consolidated Financial Statements for the fiscal year ending March 31, 2026. Alongside the financial statements, the company has also provided the respective audit reports issued by its Statutory Auditors. These audited results are subject to final adoption by the shareholders at the forthcoming Annual General Meeting of the Company.
Accessibility of Information
For the convenience of stakeholders, the audited financial statements for the year ended March 31, 2026, are also readily available on the company’s official website. Investors can access this information on the ‘investors’ section of the website at https://www.kimshospitals.com/investors/. The company has provided this update for the information and records of the concerned parties.
Audit Report Highlights
The audit report from S.R. Batliboi & Associates LLP, dated May 15, 2026, confirms the fair presentation of the financial statements. Key audit matters highlighted include the impairment assessment of investments in loans to subsidiaries, with auditors detailing their procedures to test management’s assessments. The auditors also addressed other legal and regulatory requirements, including their opinion on the adequacy of internal controls and adherence to various sections of the Companies Act, 2013.
Financial Performance Summary
The financial statements reveal a revenue from operations of ₹39,646 million for the year ended March 31, 2026, an increase from ₹30,022 million in the previous year. Profit for the year attributable to equity shareholders stood at ₹2,414 million, compared to ₹3,029 million in the prior year. Earnings per share (EPS) were reported at ₹6.52 for the current year, down from ₹7.57 in the preceding year.
Balance Sheet Snapshot
As of March 31, 2026, the company’s Total Assets amounted to ₹87,587 million, with Total Equity reported at ₹24,189 million. Total Borrowings (non-current and current) were ₹32,440 million. The Net Debt to Equity Ratio stands at 141% as of March 31, 2026, compared to 86% as of March 31, 2025, indicating an increase in leverage.
Consolidated Financials Overview
The consolidated financial statements present a broader financial picture, reflecting the combined performance of the Group and its subsidiaries. Total Revenue from operations for the consolidated entity reached ₹38,554 million for the year ended March 31, 2026. Consolidated Profit for the year attributable to equity shareholders was ₹2,423 million, with consolidated EPS at ₹6.03.
Source: BSE
